Presentation is loading. Please wait.

Presentation is loading. Please wait.

Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan.

Similar presentations


Presentation on theme: "Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan."— Presentation transcript:

1 Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan

2 CHA 2 DS 2 -VASc Lip GY, et al., Chest 137, , 2010 maximum score is 9 since age may contrubute 0, 1, or 2 points

3 CHA 2 DS 2 -VASc – overall event rates %/year CHA 2 DS 2 -VASc No of patients Stroke and systemic embolism

4 CHA 2 DS 2 -VASc – overall event rates Major (including intracranial) bleeding CHA 2 DS 2 -VASc No of patients %/year Major Intracranial

5 Singer DE, et al. : Ann Intern Med. 151, , 2009 Better with Warfarin Worse with Warfarin CHADS 2 score The Net Clinical Benefit of warfarin by CHADS 2 score

6 D110D150Warfarin D110 BID vs. warfarin D150 BID vs. warfarin CHA 2 DS 2 -VASc Dabigatran better Warfarin better Annual rate, % Dabigatran better Warfarin better Stroke and systemic embolism (SE) ≤ p(inter)=0.81 p(inter)=0.60

7 Dabigatran better Warfarin better Dabigatran better Warfarin better D110 BID vs. warfarin D150 BID vs. warfarin Intracranial bleeding D110D150Warfarin Annual rate, % ≤ p(inter)=0.77 p(inter)= CHA 2 DS 2 -VASc

8 Conclusion  Increasing CHA 2 DS 2 -VASc scores are associated with raised risks for stroke and bleeding,  Irrespective of CHA 2 DS 2 -VASc scores dabigatran 150 mg was superior and dabigatran 110 mg non-inferior to warfarin for stroke prevention  Both dabigatran doses reduce intracranial bleeding irrespective of CHA 2 DS 2 -VASc scores Dabigatran has a favorable benefit risk profile compared to warfarin in patients with low to high CHA 2 DS 2 -VASc scores


Download ppt "Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan."

Similar presentations


Ads by Google